Skip to main content

Table 3 Results of tumor-infiltrating lymphocyte growth, activity and therapy

From: Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma

Variable

n

%

Number of patients with tumor resected

22

 

TIL growth

  

 Yes

18

82

 No

4

18

TIL activity

  

 Reactive

12

67

 Non-reactive

3

17

 Not tested

3

17

Treatment after metastasectomy

  

 TIL

11

50

 No TIL

11

50

Reasons not to receive TIL therapy

  

 NED

1

5

 TIL did not grow

4

18

 TIL was not reactive

2

9

 Rapid disease progression

3

16

 Enrollment on another protocol

1

5

 Death

0

0

Objective response to TIL

  

 Complete response

1

9

 Partial response

4

36

 No response (disease progression)

6

55

Median time (days) to receive TIL

37

 

Average time (days) to receive TIL (range)

84 (35–416)

 
  1. TIL, tumor-infiltrating lymphocyte; NED, no evidence of disease.